发明名称 RBM3 as a marker for malignant melanoma prognosis
摘要 A method for determining whether a mammalian subject having a malignant melanoma belongs to a first or a second group, wherein the prognosis of subjects of the first group is better than the prognosis of subjects of the second group is provided. The method comprises the steps of: evaluating an amount of RBM3 protein in at least part of a sample earlier obtained from the subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group.
申请公布号 AU2009339802(B2) 申请公布日期 2014.07.24
申请号 AU20090339802 申请日期 2009.12.17
申请人 ATLAS ANTIBODIES AB 发明人 UHLEN, MATHIAS;PONTEN, FREDRIK;JIRSTROM, KARIN
分类号 G01N33/574 主分类号 G01N33/574
代理机构 代理人
主权项
地址